kidney cancer Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
New/Updated Trials
Online Trials
Age Group

Male only (6)
Female only (2)
Any (357)
N/A (1)

Phase 1 (78)
Phase 2 (76)
Phase 3 (15)
Phase 4 (5)
Phase 1/2 (39)
Phase 2/3 (2)
Unknown (151)

Interventional (271)
Observational (87)

National Cancer Institute (NCI) (28)
Memorial Sloan Kettering Cancer Center (9)
M.D. Anderson Cancer Center (7)
Merck Sharp & Dohme LLC (6)
Dana-Farber Cancer Institute (5)
Bristol-Myers Squibb (4)
City of Hope Medical Center (4)
Jonsson Comprehensive Cancer Center (4)
University Health Network, Toronto (4)
University of Texas Southwestern Medical Center (4)
Children's Oncology Group (3)
Duke University (3)
Fox Chase Cancer Center (3)
Hospices Civils de Lyon (3)
NGM Biopharmaceuticals, Inc (3)
Pfizer (3)
St. Jude Children's Research Hospital (3)
UNC Lineberger Comprehensive Cancer Center (3)
University of Southern California (3)
Zealand University Hospital (3)
AstraZeneca (2)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2)
AvenCell Europe GmbH (2)
Centre Leon Berard (2)
Chongqing Precision Biotech Co., Ltd (2)
Emory University (2)
Exelixis (2)
Frede Donskov (2)
HiFiBiO Therapeutics (2)
Incyte Corporation (2)
Inhibrx, Inc. (2)
Institut Cancerologie de l'Ouest (2)
Jason J. Luke, MD (2)
Mayo Clinic (2)
NRG Oncology (2)
Novartis Pharmaceuticals (2)
RenJi Hospital (2)
Seattle Children's Hospital (2)
Second Affiliated Hospital of Guangzhou Medical University (2)
Shanghai Junshi Bioscience Co., Ltd. (2)
Stanford University (2)
The Christie NHS Foundation Trust (2)
The Netherlands Cancer Institute (2)
Tianjin Medical University Second Hospital (2)
University College, London (2)
University Hospital, Strasbourg, France (2)
University of Alabama at Birmingham (2)
University of Chicago (2)
University of Florida (2)
VastBiome (2)
Washington University School of Medicine (2)
West China Hospital (2)
Xencor, Inc. (2)
Yale University (2)
Yonsei University (2)
3D Medicines (Sichuan) Co., Ltd. (1)
ADC Therapeutics S.A. (1)
AHS Cancer Control Alberta (1)
AIO-Studien-gGmbH (1)
AVEO Pharmaceuticals, Inc. (1)
Aarhus University Hospital (1)
Abramson Cancer Center of the University of Pennsylvania (1)
Actuate Therapeutics Inc. (1)
Adela, Inc. (1)
Adept Bio (1)
AeRang Kim (1)
Antoinette J Wozniak (1)
Apollomics Inc. (1)
Aravive, Inc. (1)
Aulos Bioscience, Inc. (1)
Azienda Ospedaliero-Universitaria Careggi (1)
Barbara Ann Karmanos Cancer Institute (1)
Bayer (1)
Baylor College of Medicine (1)
Beijing Sanbo Brain Hospital (1)
Beth Israel Deaconess Medical Center (1)
Birmingham Women's and Children's NHS Foundation Trust (1)
Bispebjerg Hospital (1)
Bradley A. McGregor (1)
CCTU- Cancer Theme (1)
CRISPR Therapeutics AG (1)
Cambridge University Hospitals NHS Foundation Trust (1)
Cedars-Sinai Medical Center (1)
Celldex Therapeutics (1)
Centre Francois Baclesse (1)
Centre Hospitalier Universitaire de Saint Etienne (1)
Changhai Hospital (1)
Checkpoint Therapeutics, Inc. (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Children's Hospital Medical Center, Cincinnati (1)
Children's Hospital of Philadelphia (1)
Children's Hospitals and Clinics of Minnesota (1)
Children's National Research Institute (1)
Ciprian Catana, MD, PhD (1)
Corporacion Parc Tauli (1)
DNAtrix, Inc. (1)
Daiichi Sankyo, Inc. (1)
Dan Zandberg (1)
Delfi Diagnostics Inc. (1)
Dr. Ronnie Shapira (1)

No (336)
Yes (30)

Updated trials (29)

No (366)

Adult (18+) (364)
Pediatric (Under 18) (61)

I am/have/had

I am/have/hadmetastatic renal cell carcinoma

I am/have/hadnephrectomy

I am/have/hadrenal neoplasm

I am/have/hadmeasurable disease

I am/have/hadHER2

I am/have/hadEGFR

I am/have/hadcarcinoma

I am/have/hadtumor cells

I am/have/hadmetastasis

I am/have/hadprogressive disease

I am/have/hadplatelet count

I am/have/hadmajor surgery

I am/have/hadclear cell renal cell carcinoma

I am/have/hadvegf

I am/have/hadsarcoma

I am/have/hadsolid tumour

I am/have/hadadvanced renal cell carcinoma

I am/have/hadstem cell transplantation

I am/have/hadrenal function

I am/have/hadvascular endothelial growth factor

added new label for I am/have/had

I am looking for

I am looking forsunitinib

I am looking forinterleukin-2

I am looking forinterferon

I am looking foraldesleukin

I am looking forchemotherapy drugs

I am looking formonoclonal antibodies

I am looking forbevacizumab

I am looking forcalcium

I am looking forvegf

I am looking forcombinations

I am looking forhormone therapy

I am looking foraxitinib

I am looking fordenosumab

I am looking fortumor markers

I am looking forvascular endothelial growth factor

I am looking forimmune checkpoint inhibitor

I am looking forantibiotics

I am looking foripilimumab

I am looking forfilgrastim

I am looking forpembrolizumab

added new label for I am looking for

Advanced Filters

Found 366 clinical trials

Featured trial

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
For all genders
Recruiting

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

clear cell carcinoma

metastatic cancer

carcinoma

clear cell renal cell carcinoma

primary cancer

210 views
22 Dec, 2020
1 location

Featured trial

For pediatric ages
For all genders
Recruiting

AREN03B2: Study of Kidney Tumors in Young Patients

36 views
08 Nov, 2020
1 location

Featured trial

For pediatric ages
Recruiting

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

106 views
08 Nov, 2020
1 location

Featured trial

Phase 1
For Seniors
For adults
For all genders
Family Medicine
Recruiting

A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

renal function tests

programmed cell death 1 ligand 1

renal cell cancer

cancer

measurable disease

2 views
23 Nov, 2020
3 locations

Featured trial

Phase 1
For Seniors
For adults
For all genders
Family Medicine
Recruiting

A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

systemic therapy

carcinoma

nivolumab

VEGFR2

tyrosine

57 views
15 Sep, 2020
1 location

Featured trial

For pediatric ages
For adults
For all genders
Recruiting

Procurement of Human Biospecimens for Research

53 views
23 Nov, 2020
1 location

Featured trial

For pediatric ages
For adults
For all genders
Recruiting

Procurement of Human Biospecimens for Research

80 views
23 Nov, 2020
1 location

Multi-country trial
Phase 1
Recruiting in 100s
Interventional Study
For all genders
Family Medicine
Recruiting

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

This is first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer. DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, …

carcinoma

clear cell renal cell carcinoma

mtor inhibitor

vegf

rad001